BioXcel Therapeutics Q1 2024 Earnings Call Transcript

Quartr
Provided by Quartr
May 9, 2024

There are 10 speakers on the call.

Operator

Good morning, and welcome to the BioXcel Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. After the formal remarks, there will be a question and answer session. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward looking statements subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward looking statements.

Operator

Risk factors that may affect future results are detailed in the company's annual report on Form 10 ks for the year ending December 31, 2024, which can be found at bioexceltherapeutics.comoronwwsec.gov and which will be updated in its quarterly report on Form 10 Q for the quarterly period ended March 31, 2024. As a reminder, today's call is being recorded. Speaking on today's call are Doctor. Vimal Mehta, Chief Executive Officer Doctor. Vince O'Neill, Chief of Product Development and Medical Officer and Richard Steinhardt, Chief Financial Officer.

Operator

They will be joined in the Q and A session by Doctor. Frank Yaccha, Chief Scientific Officer Matt Wiley, Chief Commercial Officer and Doctor. Rob Reisinger, Chief Medical Officer of Neuroscience. It is now my pleasure to turn the call over to Doctor. Mehta.

Operator

Please go ahead.

Speaker 1

Thank you, operator. Good morning and thank you for joining us. 2024 has been an important period of progress for BioXcel Therapeutics, both at the program and corporate levels. Starting with our neuroscience program, our journey with BXCL501 is well underway to expand the market potential for our agitation portfolio into the retail setting. We are focused on potentially bringing this novel treatment option for bipolar and schizophrenia related agitation into the home setting, we are also dedicated to expanding into a much larger indication Alzheimer's related agitation, both in the in care and home setting.

Speaker 1

We believe these two opportunities are unique with no known FDA approved therapies and represent transformative value drivers for the company and our shareholders. We are pleased to be advancing the plans for both late stage Tranquility and serenity programs, While Vince will discuss the details of these programs shortly, I want to point out that we believe serenity@homemayprovideuswithaneartermopportunitytocreate shareholder value through a potential label expansion for the previously approved 120 microgram dose. The Tranquility in care trial is similar in design to our positive Phase 3 Tranquility II trial. We see a larger long term growth potential with this program. We believe there is a significant upside to be the 1st to enter this untapped market.

Speaker 1

In addition to progressing our clinical development program, we have further expanded intellectual property for our neuroscience franchise. We were recently granted 2 new patents in U. S. And Japan. We believe this provides long term protection for our assets and gives us a solid foundation from which to pursue further development of BXCL501 and potential partnerships in key international markets.

Speaker 1

Our IP portfolio is substantial. As of April 2024, we have 30 granted or allowed patents and more than 140 additional patent applications in prosecution. We also have 8 U. S. Patents for our approved drug, IgAme, listed in the FDA's orange book, with 2 additional recently allowed patents eligible for listing once issued by the U.

Speaker 1

S. Patent and Trademark Office. Turning to egalmic commercialization traction, our revised and focused strategy is yielding results as we increased net revenue in the Q1 2024 by 55% over the Q4 2023. This growth is being primarily driven by volume contracting, new customer acquisitions, increased utilization from existing customers, and the recently implemented permanent J code for Egami. We are seeing this momentum carrying forward into the 2nd quarter, with carton volume already exceeding that of the Q1 this year.

Speaker 1

We are pleased that egalmi is reaching a greater number of patients and healthcare providers and expect this momentum to continue. Both institutional and home setting market for bipolar and schizophrenia related agitation are symbiotic and commercially strategic. We are excited about achieving an uptick in ecom utilization and having a clear development path for the home side. Turning now to the corporate front, we are pleased to have completed the $25,000,000 registered direct offering we recently announced. This transaction provides an important bridge to continue advancing our business strategy and clinical trial plans.

Speaker 1

We remain focused on further strengthening our balance sheet and exploring multiple financing options, including potential partnerships to extend our cash run. We also continue to optimize operational efficiencies. To wrap up, we believe our business fundamentals are strong. We are advancing 2 late stage clinical programs, strengthening intellectual property, and seeing progress with commercialization of eGALME. These accomplishments are underpinned by a compelling value proposition for driving future growth for the company.

Speaker 1

With that, I will turn it over to Vince.

Speaker 2

Thank you, Vimal. I appreciate the opportunity to review the progress we've made with our late stage clinical development programs for 501. So since speaking with you in March, we've received the minutes from our meetings with FDA regarding the development plans for the Tranquility and serenity programs. Based on that feedback, we have developed and announced the designs of both pivotal Phase III trials. We are pleased to have clarity on development paths, which may lead to 2 potential sNDA submissions, both for Alzheimer's related agitation and bipolar and schizophrenia related agitation.

Speaker 2

As a reminder, in the Tranquility program, we're evaluating 501 as an acute treatment for agitation associated with Alzheimer's dementia. Our Tranquility in care trial is designed as a double blind placebo controlled multicenter study to evaluate the efficacy and safety of a 60 microgram dose of 501 over a 12 week period. The primary endpoint is change in PEG score at 2 hours post first dose. It's important to note that this is the same endpoint used in previous positive tranquility trials and in studies that supported the FDA approval of Egalmi. In the serenity program, we're evaluating the potential at home use of 501 for agitation associated with bipolar disorders or schizophrenia.

Speaker 2

Our Serenity at home trial is designed to be a double blind placebo controlled multicenter study to evaluate the safety and efficacy of a 1 20 microgram dose of 501 over a 12 week period. The primary objective is safety with efficacy measures as exploratory endpoints. Again, we've taken a thoughtful and deliberate approach to our trial designs with the ultimate goal of accessing the retail setting in mind, and we look forward to advancing our plans. The trial protocols have now been finalized and are being shared with the FDA and our CROs for clinical site selection. In our PMR study, we recently completed the enrollment of 22 patients with frequent episodes of agitation for bipolar disorders or schizophrenia in that open label study.

Speaker 2

It's designed to evaluate whether tolerance, tachyphlaxes or withdrawal occur following repeat dosing of the 180 microgram dose of Igalmi after 7 days of repeated treatment. These trial results can help address the language around limitations of use and warnings and precautions in Agalami's current label. We are performing data cleaning currently and look forward to announcing results from this PMR study shortly. I'd like to end my remarks with a few comments about our lead immuno oncology asset 701. Earlier this year, we announced the completion of patient enrollment in the safety portion of the Phase 2 trial of 701 in combination with KEYTRUDA in metastatic pancreatic ductal adenocarcinoma.

Speaker 2

The trial is being led by Georgetown Lombardi Comprehensive Cancer Center. We are pleased that a late breaking abstract was selected for presentation at the 2024 ASCO Annual Meeting and look forward to sharing the data on June 1 with you. We have formally initiated the process for monetization of this asset. I would now like to turn the call over to Rich, who will review our financial results for the Q1 of 2024. Richard?

Speaker 3

Thank you, Vince. Net revenue from Algami was $582,000 for the Q1 of 2024 compared to $206,000 for the same period in 2023, a 182% year over year increase. Sequential quarterly revenue increased 55% in the Q1 of 2024 from the Q4 of 2023. Increased revenue for both periods was primarily attributable to increasing demand with our existing customer base, the addition of new customer orders and volume based contracting. Research and development expenses were $11,400,000 for the Q1 of 2024 compared to $27,800,000

Speaker 4

for

Speaker 3

the same period in 2023. The decreased expenses were primarily attributable to the wind down of the Serenity III and the Tranquility II and III trials, as well as decreased professional fees, personnel and related costs. Selling, general and administrative expenses were $13,300,000 for the Q1 of 2024 compared to $23,600,000 for the same period in 2023. The reduced expenses were primarily attributable to a decrease in personnel and costs associated with the commercialization of Algami compared to the Q1 of 2023. Reduced expenses were partially offset by increased professional fees during the Q1 of 2024.

Speaker 3

BioXcel Therapeutics had a net loss of $26,800,000 for the Q1 of 2024 compared to a net loss of $52,800,000 for the same period in 2023. The company used approximately $17,700,000 in operating cash during the Q1 of 2024. Cash and cash equivalents totaled $74,100,000 as of March 31, 2024. This includes the $25,000,000 from the registered direct offering announced on March 25, 2024. This investment extends our cash runway beyond our previous guidance of mid-twenty 24 into the second half of twenty twenty four.

Speaker 3

Now, I'd like to turn the call back to Vin.

Speaker 1

Thank you, Rich. I'd like to add that in the coming weeks, we plan to attend several upcoming Investor Healthcare Conferences and look forward to continuing our discussions. We would now like to open the call for questions. Operator?

Speaker 4

So I think the major questions investors are wrestling with are what is the timeline, the data approval in Alzheimer's agitation? And what do you expect the cost of this program to be? And then just as a kind of follow on from that, with regards to this path to approval in Alzheimer's agitation, can you say what FDA has specifically said regarding the need for the 12 month safety data? Thank you.

Speaker 5

Hi. Can you please check and see if the speaker line is muted? We're not able to hear you. Once again, we're not able to hear the Hello. We can hear audio now.

Speaker 5

Are the speakers there?

Speaker 2

Can you hear us now?

Speaker 5

Yes, we can.

Speaker 2

Okay. So sorry, we have a technical glitch on this side. So, Collyn, thanks for the question. Just to try and answer that, I'm sorry for the delay. We can't give specific dates today this morning, but what I can say in terms of the TRANQUILITY in CARE study, look to TRANQUILITY 2, the very similar trials and design.

Speaker 2

So we would anticipate a timeline and a cost very similar to the TRANQUILITY-two study.

Speaker 4

Okay. And on the FDA requirement for 12 month safety?

Speaker 2

Yes. So I think as we've said, we will re approach the FDA to discuss specifically the details around the long term safety trial, but the need for that trial is clearly not in doubt. That has to be done and that would form part of the package for the TRANQUILITY in care, sNDA.

Speaker 4

Okay. Thank you.

Speaker 5

Our next question is from Ram Salvaraju with H. C. Wainwright. Please proceed.

Speaker 4

Hi, thanks so much for taking my question. With respect to Ygalmi, can you offer us some additional color regarding the status of group contracting discussions and when you anticipate the impact to net revenue to manifest itself in the coming quarters? Are there any important GPO purchasing contracting decisions expected in the coming months please?

Speaker 6

Yes. Good morning. This is Matt. So yes, the answer to the question is we continue to matriculate contracts. We had multiple contracts in Q1.

Speaker 6

We continue to execute the plan. And over Q2, we've seen an increase in unit volume. In fact, as Vimal said in the prepared remarks, we've already seen unit volume increase more than what we posted in Q1 so far in Q2. So the contracting strategy, the volume of contracting strategy is working. We see that existing customers continue to order and we also see the acquisition of new accounts, which I think is really important for continued growth throughout the year.

Speaker 4

And then secondly, with respect to the earlier stage neuroscience assets, Are you exploring strategic options for these or is the aim to effectively continue to develop them in house?

Operator

Thank you.

Speaker 1

Ram, this is Vimal. Our focus, as I mentioned, is primarily on the 2 late stage clinical programs, serenity at home and tranquility in care. We are dedicating all our resources to those programs, but early programs certainly will be explored if there is interest for potential partnership And that we plan to explore.

Speaker 5

Our next question is from Alex Stranahan with Bank of America. Please proceed.

Speaker 7

Hey, guys. Good morning. Thanks for taking our questions. Just 2 from us. Maybe both on the metastatic PDAC data we should be expecting at ASCO.

Speaker 7

I guess maybe just high level walk us through how 701 is designed to treat these patients? And then as a follow-up, what would we typically expect with KEYTRUDA monotherapy in this line of treatment in these patients? Thanks.

Speaker 2

Sure. Good morning, Alex. This is Ben. So I'll take your second the second part of your question first. KEYTRUDA is not active as a monotherapy.

Speaker 2

I think that's generally accepted. Pancreatic cancer is a very, very cold tumor, really the definition of a cold tumor. The only exception would be MSI high pancreatic cancer. KEYTRUDA has a separate label to cover tissue agnostic MSI high patients. So that's 1% approximately of pancreas.

Speaker 2

So KEYTRUDA is not active there. Our approach is to combine with KEYTRUDA, so 701 plus KEYTRUDA in a combination. It's second line refractory pancreatic cancer, approximately 40 patients in total, Simon 2 stage, stage 1 about 20 patients followed by another 20 patients. So that's the general gist of the approach. The reason we're doing the study at all is because we have very strong and encouraging preclinical data for the combination, which we've presented.

Speaker 2

And just lastly, on the point that pancreas is a co tumor, and it's also surrounded, as you'll know, by a fibrous layer, which again makes it very difficult to treat. We've now published data that show that 701 essentially makes that collagen disappear. So there's multiple reasons to anticipate encouraging results and you'll see those results in June at ASCO.

Speaker 1

Great. Thank you.

Speaker 5

Our next question is from Afantika Joshi with Mizuho Securities. Please proceed.

Operator

Hi. Can you hear me?

Speaker 5

Yes.

Speaker 2

Okay.

Operator

Hi. This is Ivanka on for Greg. Our question is between Tranquility in care and serenity at home, which trial would you say is the priority for you guys? And would you run these studies concurrently or would it make more sense to run them one after another? Thanks.

Speaker 1

Thanks, Avantika. Strategically, we would prefer to run both trials in parallel. As I indicated, both are big value drivers for the company. There are no approved FDA therapies and they represent the transformative value drivers. Serenity, on one hand, is a near term opportunity through label expansion for the 120 microgram approved dose, while Tranquility is a much larger and longer term opportunity with a significant upside and being first to market.

Speaker 1

So to answer your question, we prefer to run both. If we have to, then we will take the decision of prioritizing one over the other or stepwise approach.

Operator

Thank you.

Speaker 5

Our next question is from Sumant Kulkarni with Canaccord Genuity. Please proceed.

Speaker 8

Good morning. Thanks for taking my questions. I had 3. So on how would you frame the capital needs that you for running Tranquility and Serenity as they stand now relative to your current cash and the additional $25,000,000 that you need to raise in November to conform to your financing agreement? That's the first.

Speaker 1

Hi, Sumant. This is Vimal. As Vince indicated, Tranquility in care trial is very similar to the Tranquility II trial where we had the positive data. We are trying to have another So we expect the trial cost to be very similar to the Tranquility. So we have very good idea about what the per patient cost is.

Speaker 1

And in terms of time lines, it will be pretty much similar. While when we think of the serenity at home, it's much smaller number of patients, almost 100 patients. So that is recruitment is much faster, what we have observed in our previous C trials, serenity 1, 23, and cost is much lower, almost 50% of what it would be in a tranquility. So we are trying to look at both opportunity. And as you know, with serenity, we can be potentially, if we can complete the trial file as NDA in 2025.

Speaker 1

So and it's very synergistic because we already have a commercial product. So I would say that we have very good handle. And based on our current cash, which was reported at $74,000,000 We are laying out what the trial cost is and what the capital requirement is and how to finance the trials and previously answered, then we prioritize or we use a stepwise approach.

Speaker 8

Got it. And then I'll ask the second and third question in one shot here. So in Tranquility in care, what's a general target percentage of patients you expect to enroll that might already be on Raxalti as a chronic treatment for agitation in Alzheimer's? And going back to cost, do you think that the operating expense base at the company as it stands currently is optimized relative to the things you need to execute on?

Speaker 2

So on RAS Alti, I'll ask my colleague, Doctor. Reisinger, to come in here. I don't think we exclude or

Speaker 7

We do not exclude patients who are on Rexulti or any other antipsychotic. And I'll point back to the TRANQUILITY II data, which demonstrated about 50% of patients are on concomitant antipsychotics.

Speaker 2

And your last question, Sumayath, I'm sorry, can I ask you to repeat it?

Speaker 8

Yes, sure. Do you think the operating expense base at the company as it stands currently is optimized relative to all the things that you need to execute on in the near to midterm here?

Speaker 3

Yes. Thanks, Suwad. It's Richard. How are you? The answer is we continually to evaluate we continue to evaluate the operating overhead and we continue to look at ways to make it more efficient and optimize it.

Speaker 3

So that's an ongoing process here. Thanks.

Speaker 5

Our next question is from Samir Devani with Rx Securities. Please proceed.

Speaker 9

Hi, guys. Thanks for taking my question. I just wanted to come back to the comment about the 12 month safety study that would be required for the TRANQUILITY in care study. I just want to confirm that, that would be required before you make the sNDA. And also, now that you've essentially completed these discussions with the FDA, what's the trigger left now to initiate that trial?

Speaker 9

Thanks very much.

Speaker 2

Good morning. This is Ben. So I think as we've said, we will go to the FDA and discuss the not the need of course for long term safety, that's clear. But the details and that will fundamentally be around the data that we collect in the study. So it's going to be a protocol discussion, which of course is why typically why we go and discuss things with the FDA.

Speaker 2

In terms of the I think your question was maybe around the numbers and requirements. I mean, those are obviously set by ICH guidelines, so 306 months and 100 at 1 year. We would need the long term safety data to support an sNDA submission.

Speaker 1

And Samir, to answer your question, when do we expect to initiate this study? As Vince mentioned, now we are sharing the protocol with the FDA and given it to the CROs for site selection. And once we have the financing in place up to the data readout, we will initiate the study. We are getting the technical readiness, right?

Speaker 5

The call back over to management for

Speaker 2

closing remarks.

Speaker 1

Thank you everyone for joining us today and for your continued interest in BioXcel Therapeutics. Have a great day.

Speaker 5

Thank you. This will conclude today's conference. You may disconnect your lines at this time and thank you for your participation.

Powered by Quartr
Earnings Conference Call
BioXcel Therapeutics Q1 2024
00:00 / 00:00